Gilead's antiviral drug comes through in hep B; Sanofi and MannKind call it quits;

@FierceBiotech: The scoop on every new drug approved in 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Annapurna adds three new gene therapy programs from Ron Crystal's lab at Weill Cornell. Story | Follow @JohnCFierce

@DamianFierce: I cannot prove that OncoCyte got its name from this generator, but I will take credit anyway. Website | Follow @DamianFierce

> Gilead Sciences' ($GILD) antiviral therapy tenofovir alafenamide measured up to the company's approved Viread in a pair of hepatitis B studies. The treatment is also a major part of Gilead's HIV pipeline. News

> Baxalta ($BXLT) and partner CTI BioPharma ($CTIC) submitted pacritinib, a myelofibrosis treatment, for FDA approval. More

> Sanofi ($SNY) and MannKind ($MNKD) are dissolving their diabetes partnership after the latter's inhalable insulin treatment failed to meet expectations. Story

Medical Device News

@FierceMedDev: NIH backs smartphone-based artificial pancreas trials with almost $13M. More | Follow @FierceMedDev

@EmilyWFierce: Pathway Genomics scores $40M in Series E round for genetic test development. Story | Follow @EmilyWFierce

@VarunSaxena2: ICYMI: Scottish researchers develop ingestible 'pill camera' that images non-visible light to detect cancer. More | Follow @VarunSaxena2

> FDA cracks down on transvaginal mesh devices amid safety concerns. More

> Pathway Genomics scores $40M in Series E round for genetic test development. Article

Pharma News

@FiercePharma: Roche resolves patent war with India's Glenmark over generic Tarceva. More | Follow @FiercePharma

@EricPFierce: 18 months after the #FDA slapped Cadila with a Form 483, it sends a warning letter. News | Follow @EricPFierce

@CarlyHFierce: ICYMI: Shire could nab Baxalta for $32B this week: Bloomberg. Story | Follow @CarlyHFierce

> Teva and Takeda fill in details on new Japan generics JV. More

> Lilly falls short of analyst forecasts with 2016 guidance on the 'weaker end.' Article

Pharma Manufacturing News

> Cadila to buy Zoetis animal drugs and feed plant in India for $29M. Item

> FDA slaps two Cadila facilities with warning letters. More

> Orchid gets favorable report for its formulation facility near Chennai. Story

> Reuters: J&J shopping its Noramco API unit for up to $800M deal. News

> FDA unveils new pharma manufacturing program as part of draft guidance. More

Drug Delivery News

> Clearside announces positive Phase II results in win for back-of-the-eye drug delivery. Story

> Halozyme picks up $150M credit deal on its Roche, Baxalta royalties. More

> Amgen partners with Unilife on wearable injectors, may buy 20% stake in the struggling company. Article

> UCSB team makes toxic transdermal drugs safer with salt formulation. News

> FDA approves nonalcoholic formulation of cancer drug, eliminating risk of intoxication following treatment. More

Pharma Asia News

> Japan's push on innovative drugs gets a budget boost. More

> India's hep C market sets a global pace on cost, access. Report

> Indonesia pharma investment cap eyed as top firms plan new plants. Story

> Sinovac gets China FDA new drug, production nod for HFMD vaccine. Article

> EU and India set Jan. 18 date for talks on GVK drug ban. Item

Suggested Articles

Notable Labs is adding $40 million to its reserves as it scales up its capabilities with plans to take its platform worldwide.

Trefoil Therapeutics raised $28 million to push its regenerative treatment for corneal dystrophies toward the clinic.

Machine learning-powered drug discoverer Recursion Pharmaceuticals has secured $121 million in new financing for its artificial intelligence programs.